For the quarter ending 2025-09-30, MYGN made $205,700K in revenue. -$27,400K in net income. Net profit margin of -13.32%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 205,700 | 213,100 | 195,900 | 206,400 |
| Cost of revenue | 61,900 | 61,300 | 61,700 | 62,150 |
| Gross profit | 143,800 | 151,800 | 134,200 | 146,350 |
| Research and development expense | 28,200 | 25,600 | 27,500 | 28,900 |
| Sales and marketing expense | 71,000 | 71,900 | 69,200 | 71,025 |
| Legal settlements | - | - | - | -5,325 |
| General and administrative expense | 67,900 | 66,800 | 66,500 | 68,975 |
| Goodwill and long-lived asset impairment charges | 0 | 316,700 | - | 11,025 |
| Total operating expenses | 167,100 | 481,000 | 163,200 | 174,600 |
| Operating loss | -23,300 | -329,200 | -29,000 | -33,500 |
| Interest income | 500 | 200 | 300 | 450 |
| Interest expense | 3,800 | 1,500 | 800 | 600 |
| Other | 400 | -100 | 100 | 1,100 |
| Total other income (expense), net | -2,900 | -1,400 | -400 | 950 |
| Loss before income tax | -26,200 | -330,600 | -29,400 | -32,550 |
| Income tax expense (benefit) | 1,200 | -100 | -29,300 | 1,700 |
| Net loss | -27,400 | -330,500 | -100 | -34,250 |
| Basic (dollars per share) | -0.29 | -3.57 | 0 | -0.38 |
| Basic (shares) | 93,100,000 | 92,500,000 | 91,400,000 | -45,450,000 |
| Diluted (dollars per share) | -0.29 | -3.57 | 0 | -0.38 |
| Diluted (shares) | 93,100,000 | 92,500,000 | 91,400,000 | -45,450,000 |
MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)